Cite
HARVARD Citation
Rob, L. et al. (2022). Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial. Journal for immunotherapy of cancer. 10 (1), p. . [Online].